Psychedelic-derived and neuroplastogen therapeutics; Blixeprodil 6.3-pt MADRS at 24h, durable to 28 days; GM-3009 cardiac-safe ibogaine analog; spun out post-AbbVie $1.2B
No detailed funding rounds available.
Total known funding: